Immunocore Limited announced that GlaxoSmithKline (GSK) has selected the first clinical candidate as part of a discovery collaboration, resulting in an undisclosed milestone payment to Immunocore. The candidate selected ImmTAC addresses a target relevant in a number of different cancer indications including synovial sarcoma, bladder and non-small cell lung (NSCL) cancers. Immunocore will now undertake further preclinical testing and cGMP manufacture before progressing the ImmTAC to Phase I clinical development.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
39.47 USD | -0.10% |
|
+5.37% | -42.23% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-42.23% | 1.98B | |
+63.05% | 854B | |
+39.42% | 636B | |
-4.78% | 361B | |
+17.52% | 324B | |
+8.43% | 301B | |
+14.19% | 247B | |
+5.81% | 230B | |
+16.77% | 228B | |
+14.63% | 177B |
- Stock Market
- Equities
- IMCR Stock
- News Immunocore Holdings plc
- Immunocore Announces GlaxoSmithKline Selected ImmTAC Clinical Candidate in Discovery Collaboration